Hansel Laboratory Department of Pathology

Hansel Lab Publications

Click here to search for other Hansel Lab publications

  1. Prognostic factors in urothelial carcinoma of the bladder: histologic and molecular correlates. Solomon JP, Hansel DE. Adv Anat Pathol. 2015 Mar;22(2):102-12. doi: 10.1097/PAP.0000000000000050.
  2. Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion. Gupta S, Hau AM, Beach JR, Harwalker J, Mantuano E, Gonias SL, Egelhoff TT, Hansel DE. PLoS One. 2013 Nov 27;8(11):e81081. doi: 10.1371/journal.pone.0081081. eCollection 2013.
  3. The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo. Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel DE. Clin Cancer Res. 2013 Apr 1;19(7):1717-28.
  4. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Hansel DE, Amin MB, Comperat E, Cote RJ, Kn├╝chel R, Montironi R, Reuter VE, Soloway MS, Umar SA, Van der Kwast TH. Eur Urol. 2013 Feb;63(2):321-32.
  5. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Ching CB, Amin MB, Tubbs RR, Elson P, Platt E, Dreicer R, Fergany A, Hansel DE. Mod Pathol. 2011 Aug;24(8):1111-9.
  6. Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. Zhang Z, Furge KA, Yang XJ, Teh BT, Hansel DE. BMC Med Genomics. 2010 Dec 15;3:58.
  7. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, De Marzo A, Steinle RE, Hsi ED, Theodorescu D, Ching CB, Eng C. Am J Pathol. 2010 Jun;176(6):3062-72.

Page 'Breadcrumb' Navigation:

External Resources: